What is Carterra?
Carterra operates at the intersection of biotechnology and high-throughput analytics, specializing in the rapid screening and characterization of monoclonal antibodies. Through its flagship LSA, Ultra, and Vega systems, the company utilizes patented surface plasmon resonance (SPR) imaging to deliver unparalleled insights into binding kinetics and epitope mapping. This technological edge is critical for biopharmaceutical entities and research institutions engaged in complex therapeutic development, including immuno-oncology and vaccine research. By streamlining the drug discovery pipeline, Carterra effectively reduces the time-to-market for novel therapeutics, positioning itself as an essential partner in the global healthcare innovation ecosystem.
How much funding has Carterra raised?
Carterra has raised a total of $17M across 3 funding rounds:
Unspecified
$10M
Other Financing Round
$6M
Debt
$1M
Unspecified (2018): $10M with participation from Telegraph Hill Partners
Other Financing Round (2020): $6M led by Ballast Point Ventures and Telegraph Hill Partners
Debt (2020): $1M supported by PPP
Key Investors in Carterra
Telegraph Hill Partners
Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in commercial stage life science, medical technology, and healthcare companies.
Ballast Point Ventures
Ballast Point Ventures is a late venture and early growth equity investor that provides expansion capital to established but rapidly growing private companies, primarily in the Southeast and Texas.
PPP
Public-Private Partnership
What's next for Carterra?
With the recent strategic investment, Carterra is well-positioned to accelerate its commercial expansion and deepen its R&D capabilities. The company is expected to focus on scaling its manufacturing capacity to meet the growing demand for its LSA systems while simultaneously exploring new applications for its microfluidic platform in emerging therapeutic areas. As the biopharmaceutical industry continues to prioritize efficiency and precision in drug development, Carterra's ability to provide high-fidelity data at scale will likely remain a key competitive advantage. Future growth initiatives will likely center on international market penetration and the integration of advanced data analytics to further enhance the utility of its antibody analysis suite.
See full Carterra company page
